文献速递乳腺癌

美国COVID-19大流行第一年癌症治疗变化评估

Assessment of Changes in Cancer Treatment During the First Year of the COVID-19 Pandemic in the US.
PubMed 文献 · JAMA Oncol · 2024-01-01

该队列研究基于美国国家癌症数据库纳入2018至2020年诊断的任何实体瘤成人患者共3 504 342例,采用向量自回归方法估算2020年各治疗方式的预期例数并与实际观察值比较。结果显示2020年 curative intent 手术约减少98 000例、化疗方案减少38 800例、放疗方案减少55 500例、免疫治疗方案减少6 800例、激素治疗减少32 000例。多数癌种和分期的治疗类型无统计学显著变化,但大流行最初数月Ⅰ期乳腺癌保乳手术加放疗比例显著下降而乳房切除术比例显著上升。

要点

  • 2020年 curative intent 手术较预期约减少98 000例,化疗方案减少38 800例。
  • 2020年放疗方案较预期减少55 500例,免疫治疗方案减少6 800例,激素治疗减少32 000例。
  • 多数癌种和分期治疗类型无统计学显著变化,Ⅰ期乳腺癌保乳加放疗比例下降、乳房切除术比例上升。

核心结论

  • 在这项大型全国性队列研究中,COVID-19大流行第一年提供的癌症治疗数量出现显著缺口,数据提示该缺口与癌症诊断数量减少相关,而非治疗策略改变。

研究设计与样本

  • 队列研究,使用美国国家癌症数据库识别2018年1月1日至2020年12月31日诊断的任何实体瘤的18岁及以上成人。
  • 共纳入3 504 342例患者,其中2018年1 214 918例(平均[SD]年龄64.6[13.6]岁)、2019年1 235 584例(64.8[13.6]岁)、2020年1 053 840例(64.9[13.6]岁)。
  • 数据分析时间为2022年9月19日至2023年7月28日。
  • 使用2018年1月1日至2019年12月31日的历史数据,以向量自回归方法计算2020年各治疗方式(手术、放疗、化疗、免疫治疗、激素治疗)的预期例数。
  • 采用泊松分布假设下的广义估计方程评估预期例数与观察例数之间的差异,并使用加性离群值方法评估2020年启动的不同类型癌症治疗比例的变化。

主要发现

  • 与既往趋势的预期治疗相比,2020年 curative intent 手术约减少98 000例,化疗方案减少38 800例,放疗方案减少55 500例,免疫治疗方案减少6 800例,激素治疗减少32 000例。
  • 对于所评估的大多数癌种和分期,大流行第一年提供的癌症治疗类型无统计学显著变化。
  • 例外情况是大流行最初数月Ⅰ期乳腺癌接受保乳手术加放疗的患者比例出现统计学显著下降,同时接受乳房切除术的患者比例出现统计学显著上升。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The COVID-19 pandemic led to disruptions in access to health care, including cancer care. The extent of changes in receipt of cancer treatment is unclear. OBJECTIVE: To evaluate changes in the absolute number, proportion, and cancer treatment modalities provided to patients with newly diagnosed cancer during 2020, the first year of the pandemic. DESIGN, SETTING, AND PARTICIPANTS: In this cohort study, adults aged 18 years and older diagnosed with any solid tumor between January 1, 2018, and December 31, 2020, were identified using the National Cancer Database. Data analysis was conducted from September 19, 2022, to July 28, 2023. EXPOSURE: First year of the COVID-19 pandemic. MAIN OUTCOMES AND MEASURES: The expected number of procedures for each treatment modality (surgery, radiotherapy, chemotherapy, immunotherapy, and hormonal therapy) in 2020 were calculated using historical data (January 1, 2018, to December 31, 2019) with the vector autoregressive method. The difference between expected and observed numbers was evaluated using a generalized estimating equation under assumptions of the Poisson distribution for count data. Changes in the proportion of different types of cancer treatments initiated in 2020 were evaluated using the additive outlier method. RESULTS: A total of 3 504 342 patients (1 214 918 in 2018, mean [SD] age, 64.6 [13.6] years; 1 235 584 in 2019, mean [SD] age, 64.8 [13.6] years; and 1 053 840 in 2020, mean [SD] age, 64.9 [13.6] years) were included. Compared with expected treatment from previous years' trends, there were approximately 98 000 fewer curative intent surgical procedures performed, 38 800 fewer chemotherapy regimens, 55 500 fewer radiotherapy regimens, 6800 fewer immunotherapy regimens, and 32 000 fewer hormonal therapies initiated in 2020. For most cancer sites and stages evaluated, there was no statistically significant change in the type of cancer treatment provided during the first year of the pandemic, the exception being a statistically significant decrease in the proportion of patients receiving breast-conserving surgery and radiotherapy with a simultaneous statistically significant increase in the proportion of patients undergoing mastectomy for treatment of stage I breast cancer during the first months of the pandemic. CONCLUSIONS AND RELEVANCE: In this large national cohort study, a significant deficit was noted in the number of cancer treatments provided in the first year of the COVID-19 pandemic. Data indicated that this deficit in the number of cancer treatments provided was associated with decreases in the number of cancer diagnoses, not changes in treatment strategies.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Nogueira LM, Schafer EJ, Fan Q, et al. Assessment of Changes in Cancer Treatment During the First Year of the COVID-19 Pandemic in the US. JAMA Oncol. 2024. PMID: 37943539. doi:10.1001/jamaoncol.2023.4513

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。